The rise of TIM-3: A promising immune target in diffuse midline gliomas

Iker Ausejo-Mauleon; Sara Nuin; Marta M. Alonso

doi:10.1002/ctm2.1536

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1536 DOI: 10.1002/ctm2.1536

EDITORIAL

The rise of TIM-3: A promising immune target in diffuse midline gliomas

Iker Ausejo-Mauleon ¹^,²^,³^,^†
, Sara Nuin ¹^,²^,³
, Marta M. Alonso ¹^,²^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Iker Ausejo-Mauleon, Sara Nuin, Marta M. Alonso. The rise of TIM-3: A promising immune target in diffuse midline gliomas. Clinical and Translational Medicine, 2024, 14(1): e1536 DOI:10.1002/ctm2.1536

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Di Ruscio V, Del Baldo G, Fabozzi F, et al. Pediatric diffuse midline gliomas: an unfinished puzzle. Diagnostics. 2022;12(9):2064.

[2]	El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria LopezV, et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol. 2019;145(1):177-184.

[3]	Ausejo-Mauleon I, Labiano S, de la Nava D, et al. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell.41(11):1911-1926.e8.

[4]	Kline C, John-Liu S, Duriseti S, et al. Reirradiation and PD-1 inhibition with nivolumab for the tratment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018;140(3):629-638.

[5]	Persson ML, Douglas AM, Alvaro F, et al. The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol. 2022;24(9):1408-1422.

[6]	Lieberman NAP, Degolier K, Kovar HM, et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 2019;21(1):83-94.

[7]	Lin GL, Nagaraja S, Filbin MG, et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2018;6(1):51.

[8]	Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N Engl J Med. 2022;386(26):2471-2481.

[9]	Laspidea V, Puigdelloses M, Labiano S, et al. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight. 2022;7(7):e154812.

[10]	Martínez-Vélez N, Garcia-Moure M, Marigil M, et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235.

[11]	Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934-941.

[12]	Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas letter. Nat Med. 2018;24(5):572-579.

[13]	Vitanza NA, Wilson AL, Huang W, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-2 human bioactivity and safety. Cancer Discov.13(1):114-131.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.